How have EVTCY shares performed in 2024?

Evotec's stock was trading at $11.73 at the beginning of 2024. Since then, EVTCY stock has decreased by 39.7% and is now trading at $7.07. View the best growth stocks for 2024 here .

When did Evotec's stock split?

Evotec shares split on the morning of Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly created shares were payable to shareholders after the closing bell on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

How do I buy shares of Evotec?

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Evotec have any subsidiaries?

The following companies are subsidiares of Evotec: Aptuit, Bionamics GmbH, Cell Culture Service GmbH, Central Glass Germany, Central Glass Germany. GmbH, Compound Focus, Cyprotex, Develogen AG, Euprotec, Evotec (India) Private Ltd, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, KINAXO Biotechnologies, Oxford Asymmetry International, RENOVIS, and Rigenerand Srl. Read More

OTCMKTS:EVTCY

Evotec (EVTCY) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free EVTCY Stock Alerts

$7.07

-0.08 (-1.12%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.00
▼
$7.10
50-Day Range: $6.89
▼
$7.87
52-Week Range: $14.22
▼
$26.57

Volume: 19,225 shs
Average Volume: 2,407 shs
Market Capitalization: $2.33 billion

P/E Ratio: 17.44
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings

Get Evotec alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Evotec Stock (OTCMKTS:EVTCY)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

EVTCY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVTCY Stock News Headlines

March 6, 2024 | finanznachrichten.de

Evotec SE: Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic

January 10, 2024 | finanznachrichten.de

Evotec SE: Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

January 4, 2024 | markets.businessinsider.com

Evotec, Owkin Anounce A.I.-Powered Collaboration In Oncology, Immunology, And Inflammation

November 12, 2023 | finance.yahoo.com

Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript

November 8, 2023 | markets.businessinsider.com

EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update

October 5, 2023 | finance.yahoo.com

65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in Singapore

September 27, 2023 | finance.yahoo.com

Evotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D Economy

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

September 21, 2023 | finance.yahoo.com

Evotec SE (EVO) Stock Historical Prices & Data - Yahoo Finance

May 30, 2023 | finance.yahoo.com

Is There Now An Opportunity In Evotec SE (ETR:EVT)?

May 14, 2023 | finance.yahoo.com

Evotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value Estimate

May 13, 2023 | finanznachrichten.de

Evotec SE: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023

May 12, 2023 | investing.com

Evotec SE ADR (EVO) Earnings Dates & Reports

May 10, 2023 | investing.com

Evotec SE ADR (EVO)

May 9, 2023 | finanznachrichten.de

Evotec SE: Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

April 10, 2023 | finance.yahoo.com

Evotec SE Provides Update on Cyber Attack

February 10, 2023 | finanznachrichten.de

Evotec SE: Evotec Receives € 150 m Loan from European Investment Bank

January 31, 2023 | markets.businessinsider.com

EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

December 22, 2022 | ca.finance.yahoo.com

With 47% ownership, Evotec SE (ETR:EVT) has piqued the interest of institutional investors

December 17, 2022 | finanznachrichten.de

Evotec SE: Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb

September 21, 2022 | finanznachrichten.de

Evotec SE: Just - Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program

September 20, 2022 | markets.businessinsider.com

Evotec: US Unit Gets $49.9 Mln Antibodies Contract From U.S. Department Of Defense

September 17, 2022 | finanznachrichten.de

Evotec SE: Evotec Initiates Ground-Breaking for New Biologics Facility J.POD Toulouse, France

August 13, 2022 | seekingalpha.com

Evotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | nasdaq.com

Evotec Slips To Loss In Q3, Revenues Rise; Lifts FY22 Revenue View, Backs Adj. EBITDA Forecast

August 11, 2022 | markets.businessinsider.com

DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates

See More Headlines

Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:EVTCY
CUSIP: N/A
CIK: 1412558
Web: www.evotec.com
Phone: (494) 056-0810
Fax: 49-40-5608-1222
Employees: 3,572
Year Founded: 1993

Profitability

EPS (Most Recent Fiscal Year): $0.41
Trailing P/E Ratio: 17.44
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $7.14 million
Net Margins: 20.85%
Pretax Margin: 23.90%
Return on Equity: 16.02%
Return on Assets: 7.81%

Debt

Debt-to-Equity Ratio: 0.53
Current Ratio: 2.57
Quick Ratio: 2.50

Sales & Book Value

Annual Sales: $572.16 million
Price / Sales: 4.13
Cash Flow: $0.07 per share
Price / Cash Flow: 105.53
Book Value: $2.52 per share
Price / Book: 2.84

Miscellaneous

Outstanding Shares: 330,221,000
Free Float: N/A
Market Cap: $2.36 billion
Optionable: Not Optionable
Beta: 0.98

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Werner Lanthaler
Chief Executive Officer
Craig L. Johnstone
Chief Operating Officer & Member-Management Board
Enno Spillner
Chief Financial Officer
Cord E. Dohrmann
Chief Scientific Officer
Volker Braun
SVP, Head-Investor Relations & ESG

Key Competitors

View All Competitors

EVTCY Stock Analysis - Frequently Asked Questions

How have EVTCY shares performed in 2024?: Evotec's stock was trading at $11.73 at the beginning of 2024. Since then, EVTCY stock has decreased by 39.7% and is now trading at $7.07.
View the best growth stocks for 2024 here.
When did Evotec's stock split?: Evotec shares split on the morning of Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly created shares were payable to shareholders after the closing bell on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.
How do I buy shares of Evotec?: Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Evotec have any subsidiaries?: The following companies are subsidiares of Evotec: Aptuit, Bionamics GmbH, Cell Culture Service GmbH, Central Glass Germany, Central Glass Germany. GmbH, Compound Focus, Cyprotex, Develogen AG, Euprotec, Evotec (India) Private Ltd, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, KINAXO Biotechnologies, Oxford Asymmetry International, RENOVIS, and Rigenerand Srl.
Read More

This page (OTCMKTS:EVTCY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial